Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural insights into tecovirimat antiviral activity and poxvirus resistance.

Nature microbiology - 1 Mar 2025

Vernuccio Riccardo, Martínez León Alejandro, Poojari Chetan S, Buchrieser Julian, Selverian Christopher N, Jaleta Yakin, Meola Annalisa, Guivel-Benhassine Florence, Porrot Françoise, Haouz Ahmed, Chevreuil Maelenn, Raynal Bertrand, Mercer Jason, Simon-Loriere Etienne, Chandran Kartik, Schwartz Olivier, Hub Jochen S, Guardado-Calvo Pablo

Abstract excerpt

Mpox is a zoonotic disease endemic to Central and West Africa. Since 2022, two human-adapted monkeypox virus (MPXV) strains have caused large outbreaks outside these regions. Tecovirimat is the most widely used drug to treat mpox. It blocks viral egress by targeting the viral phospholipase F13; however, the structural details are unknown, and mutations in the F13 gene can result in resistance against tecovirimat,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crystallography, X-Ray

Share to Drug Resistance, Viral

Share to Molecular Dynamics Simulation

Share to Phthalimides

Share to Protein Multimerization

Share to Viral Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39939832
DOI: 10.1038/s41564-025-01936-6
PMCID: PMC11879855

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural insights into tecovirimat antiviral activity and poxvirus resistance.PMID 39939832Read ↗

Mechanisms of Tecovirimat Antiviral Activity and Poxvirus ResistanceSemantic proximity Read ↗

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read ↗

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023Semantic proximity Read ↗

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreakSemantic proximity Read ↗

Resistance to anti-orthopoxviral drug tecovirimat (TPOXX<sup>®</sup>) during the 2022 mpox outbreak in the USSemantic proximity Read ↗

Potential of Acyclovir, Allopurinol and B Vitamins for the Treatment of Mpox Viral Infection; Insight from Molecular Docking of the Mpox Virus Multi-Domain DNA PolymeraseSemantic proximity Read ↗

Mpox in the Post-2022 Era: A Comprehensive Review of Viral Evolution, Host Adaptation, and Clinical ManagementSemantic proximity Read ↗

Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat ResistanceSemantic proximity Read ↗

Structure of monkeypox virus poxin: implications for drug designSemantic proximity Read ↗

AI-assisted identification of a novel Orthopoxvirus inhibitor targeting F13Semantic proximity Read ↗

The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges.Semantic proximity Read ↗

Genomic and transcriptomic analysis of the recent Mpox outbreakSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.